Patent ID: 7531162
Filing Date: 2009-05-12
Classification: A61K,A61P,C07H

Abstract:
1. A compound of the formula (I): or its enantiomer, diastereomer or its pharmaceutically acceptable salt, wherein: (i) the wavy line in the chemical structure indicates either a dative or covalent bond such that there are three dative Co—N bonds and one covalent Co—N bond, wherein, in the case of the dative bond, the valence of nitrogen is completed either with a double bond with an adjacent ring carbon or with a hydrogen; (ii) the dotted line in the chemical structure indicates either a double or single bond such that the double bond does not over-extend the valence of the element and, in the case of a single bond, the valence is completed with hydrogen; (iii) X is hydrogen, cyano, halogen, haloalkyl, NO, NO (iv) M is a monovalent heterocycle or heteroaromatic, which is capable of binding to the adjacent sugar ring, and forming a dative bond with Co (v) K is O, S, NJ (vi) E is O or S; (vii) G (viii) Y (ix) V (x) Z (xi) each L is independently a direct bond or linker, of a singular molecular weight, to one or more T moieties, and that does not significantly impair the ability of the TC- or IF-binding carrier to bind to a transcobalamin receptor, optionally when bound to a transport protein; (xii) each T independently comprises the residue of a diagnostic agent effective for the diagnosis of a proliferative disorder, optionally bound though a chelating moiety; (xiii) at least one of Z (xiv) J (xv) R (xvi) R (xvii) R (xviii) R (xix) wherein at least one of Y, R, G, E, K, M and V is not as it is found in natural vitamin B (xx) wherein at least one -L-T is independently a poly-L-lysine-NR′(CH((CH